Education
About Us
Working with TipRanks
Follow Us
Suven Life Sciences Limited (IN:SUVEN)
:SUVEN
Top Page
Suven Life Sciences Limited
(SUVEN)
Select Model
Select Model
Rating:43Neutral
Price Target:
₹159.00
▼(-3.64% Downside)
The score is driven primarily by very weak financial performance—sharp profitability deterioration, negative gross profit, and persistent operating/free-cash-flow burn—partly offset by minimal leverage. Technicals add pressure with the stock trading below key moving averages and negative MACD, while valuation provides limited support because the negative P/E reflects ongoing losses and no dividend yield is available.
Suven Life Sciences Limited (SUVEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹36.34B
Dividend YieldN/A
Average Volume (3M)14.83K
Price to Earnings (P/E)―
Beta (1Y)1.66
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees141
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-3.48
Shares Outstanding227,474,210
10 Day Avg. Volume16,308
30 Day Avg. Volume14,834
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)24.25
Price to Sales (P/S)400.69
P/FCF Ratio-14.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Suven Life Sciences Limited Business Overview & Revenue Model
Company DescriptionSuven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
How the Company Makes Money
Suven Life Sciences Limited Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 75.17M | 66.56M | 116.93M | 135.39M | 118.44M | 134.78M |
| Gross Profit | -17.93M | -276.33M | 108.69M | 129.74M | -137.31M | 133.75M |
| EBITDA | -1.78B | -1.55B | -992.78M | -1.11B | -1.17B | -721.87M |
| Net Income | -1.84B | -1.61B | -1.05B | -1.18B | -1.22B | -721.51M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.35B | 2.85B | 3.89B | 1.08B | 1.28B |
| Cash, Cash Equivalents and Short-Term Investments | 600.05M | 600.05M | 2.40B | 2.31B | 504.36M | 463.54M |
| Total Debt | 0.00 | 0.00 | 7.10M | 16.05M | 32.09M | 47.64M |
| Total Liabilities | -1.10B | 251.97M | 148.62M | 135.91M | 118.89M | 204.12M |
| Stockholders Equity | 1.10B | 1.10B | 2.70B | 3.75B | 961.45M | 1.08B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.86B | -1.15B | -1.06B | -1.47B | -1.02B |
| Operating Cash Flow | 0.00 | -1.48B | -1.15B | -1.03B | -1.28B | -960.24M |
| Investing Cash Flow | 0.00 | 1.49B | 944.36M | -2.61B | -222.29M | 558.40M |
| Financing Cash Flow | 0.00 | -7.10M | -10.54M | 3.96B | 1.46B | 348.56M |
Suven Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹59.11B | 32.41 | ― | 0.13% | 14.35% | 15.79% | |
58 Neutral | ₹50.35B | 118.66 | ― | ― | 14.39% | 152.14% | |
57 Neutral | ₹35.15B | 17.65 | ― | 0.24% | 4.08% | 31.52% | |
57 Neutral | ₹32.08B | 56.36 | ― | 0.03% | 7.78% | -34.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | ₹42.98B | -16.10 | ― | ― | -0.82% | 34.67% | |
43 Neutral | ₹36.34B | -16.55 | ― | ― | ― | ― |
* Healthcare Sector Average
IN:SUVEN
Suven Life Sciences Limited
159.75
25.55
19.04%
IN:AARTIDRUGS
Aarti Drugs Limited
385.10
-36.55
-8.67%
IN:GUFICBIO
Gufic Biosciences Limited
319.90
-155.87
-32.76%
IN:SEQUENT
Sequent Scientific Limited
198.15
27.35
16.01%
IN:SPARC
Sun Pharma Advanced Research Co. Ltd.
132.45
-42.10
-24.12%
IN:SUPRIYA
Supriya Lifescience Limited
734.40
65.66
9.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.